Gene Sequencing

In a federal class action, shareholders claim directors of Illumina (gene sequencing) issued misleading earnings estimates, and when true earnings were reported the share price sank by 24.8% in one day, from $224.85 to $139.

SAN DIEGO – In a federal class action, shareholders claim directors of Illumina (gene sequencing) issued misleading earnings estimates, and when true earnings were reported the share price sank by 24.8% in one day, from $224.85 to $139.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.